Technology for Degrader-Antibody Conjugates to Unlock Heterobifunctional Degraders Through mAb-like Pharmacokinetics & Excellent in vivo Efficacy
Time: 2:30 pm
day: Day Two
Details:
- Payloads of current marketed ADC are limited to three Modes of Action (MoAs): DNA binders, Tubulin- and TOP-I-Inhibitors
- Exploring novel conjugation technologies for stable conjugation and traceless release of heterobifunctional degraders
- Resulting DACs are homogenous with at high DAR, have excellent linker stability, and exhibit unprecedented in vivo PK and efficacy
